Post-earnings recap
Reported
Mon, May 10, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Krystal Biotech's earnings report indicates a larger-than-expected loss per share, which contributed to a 6.91% decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's financial trajectory. Overall, the results reflect ongoing challenges in achieving profitability as the company continues to invest in its product pipeline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.74 | N/A | -35.28% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the challenges faced during the quarter. They emphasized their commitment to ongoing development efforts.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its pipeline despite the current losses.